London, March 10th, 2016.
This report is based on the findings of a Patient View November 2015-January 2016 survey exploring the views of 1,075 patient groups from 72 countries, and focusing on differing medical
specialties. The report provides feedback on the corporate reputation of the pharma
industry during 2015, as well as the performance of 48 pharma companies for six key
indicators that influence corporate reputation. Results are compared with those of
the previous four years.
For
the purposes of this report, the phrase ‘corporate reputation’ is defined as
the extent to which pharma companies are meeting the expectations of patients
and patient groups.
The six indicators of corporate reputation:
- Patient-centricity.
- Patient information.
- Patient safety.
- Useful products.
- Transparency; and
- Integrity
The 48 companies analysed:
AbbVie
I Actavis I Allergan I Almirall I Amgen I Astellas Pharma I AstraZeneca I
Baxalta I Bayer I Biogen Idec I Boehringer Ingelheim I Bristol-Myers Squibb I
Celgene I Chiesi Farmaceutici I Eisai I Eli Lilly (Lilly) I Ferring I Gedeon
Richter I Gilead Sciences I Grifols I Grünenthal I GSK I Hospira I Ipsen I
Janssen Pharmaceutical Companies of Johnson & Johnson I LEO Pharma I
Lundbeck I Mallinckrodt I Menarini I Merck & Co I Merck KGaA I Mylan I
Novartis I Novo Nordisk I Octapharma I Otsuka I Pfizer I Roche I Sandoz I
Sanofi I Servier I Shire I Stada Arzneimittel I Takeda I Teva I UCB I Valeant I
ViiV Healthcare